746MO Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)

• DOI: 10.1016/j.annonc.2023.09.1925
• Publication Date: 2023-10-20T12:31:49Z
• Authors: J-M. Lee; A. Miller; P. Rose; M. AlHilli; C. Washington; V. John; C. Shah; K. Matsuo; J. Siedel; D.S. Miller; J. Chan; E. Hopp; E.C. Kohn; K.N. Moore; J.F. Liu
• Keywords: Durvalumab; Olaparib; Standard of care